Horm Metab Res 1983; 15(9): 439-443
DOI: 10.1055/s-2007-1018749
© Georg Thieme Verlag, Stuttgart · New York

Prolactin Lowering Effect of Amphetamine in Normoprolactinemic Subjects and in Physiological and Pathological Hyperprolactinemia

V. DeLeo1 , S. G. Cella3 , F. Camanni2 , A. R. Genazzani1 , E. E. Müller3
  • 1Department of Obstetrics and Gynecology, University of Modena, Italy
  • 2Department of Metabolic Diseases, University of Turin, Italy
  • 3Department of Pharmacology, University of Milan, Italy
Further Information

Publication History

1982

1982

Publication Date:
14 March 2008 (online)

Summary

The effect on plasma prolactin (PRL) of d-amphetamine (Amph) was studied in normo- and hyperprolactinemic subjects. In normoprolactinemic women Amph failed to lower plasma PRL levels when infused intravenously over 1 h at the dose of 7.5 mg, but induced at the dose of 15.0 mg a modest inhibition of plasma PRL (maximum PRL inhibition 20 ± 4.5% at 45 min). Likewise, in puerperal women Amph at the dose of 7.5 mg did not decrease significantly plasma PRL levels but it was active in this respect (maximum inhibition 37 ± 10% at 120 min) at the dose of 15.0 mg. In subjects with presumptive evidence of a PRL-secreting adenoma, Amph at either the 7.5 mg or the 15.0 mg dose failed to alter baseline PRL levels. These results indicate that Amph is a poor PRL suppressor in either normo- or hyperprolactinemic subjects. It is proposed that this may be due to the drug's ability to effect release of dopamine mainly from a non-granular pool of the amine.